Immunostimulants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Libster NCT04479163		RCT	convalescent plasma treatment	placebo	COVID-19 mild to moderate	low	80/80	conclusif	demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
PLACID CTRI/2020/04/024775		RCT	convalescent plasma treatment	standard of care	COVID-19 mild to moderate	high	235/229	suggested	inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias suggested 20 % increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis